Advances in ovarian cancer treatment using a combination of statins with other drugs

New anti-cancer drugs are constantly being developed, especially targeted drugs. Although these drugs have achieved significant clinical efficacy, they do not play a significant role in ovarian cancer. Moreover, the research cycle and costs of such drugs are often huge. The repositioning of conventi...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2023-01, Vol.13, p.1048484-1048484
Main Authors: Xia, Lei, Ding, Shichao, Wang, Xuezhen, Zhang, Xiaoyu, Zhu, Lin, Zhang, Hairong, Li, Huirong
Format: Article
Language:English
Subjects:
HMGCoA reductase
ovarian cancer
Pharmacology
progress
statins
synergistic effect
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:New anti-cancer drugs are constantly being developed, especially targeted drugs. Although these drugs have achieved significant clinical efficacy, they do not play a significant role in ovarian cancer. Moreover, the research cycle and costs of such drugs are often huge. The repositioning of conventional drugs has gradually become a concern. Statins, as traditional lipid-lowering drugs, play a role mainly by inhibiting HMGCR. In recent years, epidemiological studies and experiments have confirmed its anti-cancer effect, especially the effect of anti-ovarian cancer. The mutation rate of TP53 in ovarian cancer is as high as 95%, while HMGCR is often highly expressed in TP53 mutant tumors. However, the effect of prospective clinical trials is not ideal. This result seems understandable considering that it seems unrealistic for a lipid-lowering drug to completely inhibit tumor growth. Therefore, statins play more synergistic roles in the treatment of ovarian cancer. Because ovarian cancer is a highly heterogeneous tumor, it may be a good choice to deeply understand the mechanism of statins in the treatment of ovarian cancer and achieve precise treatment by combining it with other drugs.
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2022.1048484